Polydex Pharmaceuticals Performance
| POLXFDelisted Stock | USD 1.96 0.01 0.51% |
The company holds a Beta of -4.67, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Polydex Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Polydex Pharmaceuticals is expected to outperform it. Polydex Pharmaceuticals right now holds a risk of 0.0%. Please check Polydex Pharmaceuticals value at risk, as well as the relationship between the skewness and day median price , to decide if Polydex Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Polydex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Polydex Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Polydex |
Polydex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 196.00 in Polydex Pharmaceuticals on October 23, 2024 and sell it today you would earn a total of 0.00 from holding Polydex Pharmaceuticals or generate 0.0% return on investment over 90 days. Polydex Pharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Polydex, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Polydex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Polydex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Polydex Pharmaceuticals, and traders can use it to determine the average amount a Polydex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| POLXF |
Based on monthly moving average Polydex Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Polydex Pharmaceuticals by adding Polydex Pharmaceuticals to a well-diversified portfolio.
Polydex Pharmaceuticals Fundamentals Growth
Polydex Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Polydex Pharmaceuticals, and Polydex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Polydex Pink Sheet performance.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0824 | |||
| Profit Margin | (0.25) % | |||
| Operating Margin | (0.22) % | |||
| Current Valuation | 2.23 M | |||
| Shares Outstanding | 3.43 M | |||
| Price To Earning | 12.33 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 4.05 M | |||
| EBITDA | (568.16 K) | |||
| Cash And Equivalents | 870.3 K | |||
| Cash Per Share | 0.25 X | |||
| Total Debt | 301.49 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 1.44 X | |||
| Cash Flow From Operations | (238.54 K) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 6.56 M | |||
| Retained Earnings | (19.53 M) | |||
| Current Asset | 3.41 M | |||
| Current Liabilities | 1.28 M | |||
About Polydex Pharmaceuticals Performance
By analyzing Polydex Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Polydex Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Polydex Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Polydex Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada. Polydex Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people.Things to note about Polydex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Polydex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Polydex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Polydex Pharmaceuticals is not yet fully synchronised with the market data | |
| Polydex Pharmaceuticals may become a speculative penny stock | |
| Polydex Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Polydex Pharmaceuticals has accumulated about 870.3 K in cash with (238.54 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. |
- Analyzing Polydex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Polydex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Polydex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Polydex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Polydex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Polydex Pharmaceuticals' pink sheet. These opinions can provide insight into Polydex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stocks Directory Find actively traded stocks across global markets |